Earnings call transcript: Alkermes beats Q3 2026 estimates as sales rise

Alkermes reported Q3 2026 adjusted EPS of $0.09 versus analysts’ forecast of a $0.08 loss and revenue of $480.1 million versus $463.35 million expected; proprietary product sales rose 31% year over year to $417.3 million. The company reaffirmed 2026 guidance, including nearly $1.6 billion in full-year proprietary product sales, while shares gained 1.8% premarket to $45.70. Management expects multiple orexin-pipeline readouts through 2027, alongside higher R&D investment; clinical outcomes and rising costs remain key risks.

Analysis

The beat is less clean than the headline suggests: proprietary growth includes LUMRYZ added through the Avadel transaction, while VIVITROL benefited from roughly $8m of gross-to-net favorability and ARISTADA/Lybalvi also had stated gross-to-net or inventory benefits. Unchanged guidance and a modest initial share response argue against treating one quarter as evidence of a higher durable earnings run-rate. The cleaner operating signal is demand breadth, but verify prescription growth, persistence, and net sales conversion rather than relying on reported portfolio growth.

Near term, LYBALVI is a mix-shift risk: management expects payer expansion to support nearly 20% volume growth in 2027, but gross-to-net rising to about 45% may defer the benefit in reported sales. For 2027, lower LUMRYZ acquisition-related inventory costs could help gross profit, offset by higher R&D; the net earnings effect remains unquantified until February guidance.

The main valuation catalyst is clinical, not this quarter’s earnings: Vibrance-3 data around year-end/early 2027 can set the IH development path, followed by narcolepsy Phase III results beginning mid-2027. A weak efficacy/tolerability profile, an unfavorable FDA discussion, or higher-than-expected development spend would undermine the orexin option value. Commercially, Takeda’s entry creates pricing and new-start uncertainty; management’s claim that orexin agonists and oxybates are complementary is plausible but unproven. Track LUMRYZ new starts, switches, persistence, and payer coverage. JNJ’s antagonist approach is mechanistically distinct, not a direct read-through to ALKS efficacy.

Key Decisions for Investors

• Do not chase ALKS on the earnings beat alone; the guidance hold, acquisition-related comparability, and favorable commercial adjustments limit what this quarter establishes about normalized earnings power.
• For existing ALKS exposure, size the position around the clinical calendar rather than treating it as a low-volatility commercial-growth holding. Reassess after Vibrance-3; a credible efficacy signal with acceptable safety supports the pipeline thesis, while a weak signal or delayed FDA path is a reason to reduce.
• Watch LYBALVI’s 2027 net-sales conversion against nearly 20% expected volume growth and approximately 45% gross-to-net. If volume growth fails to materialize or sales continue to lag without an access-driven explanation, the commercial-growth thesis is impaired.
• Monitor Takeda’s launch pricing and LUMRYZ patient metrics before making a sleep-franchise trade. Rising LUMRYZ discontinuations, weaker new starts, or payer restrictions would falsify the claimed durability/complementarity thesis; current evidence is insufficient for a standalone pair trade.